Discover 447 paid clinical trials in Edmonton, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Edmonton has a research history that most cities cannot match: the first successful islet cell transplant protocol for type 1 diabetes, known worldwide as the Edmonton Protocol, was developed at the University of Alberta in 2000 and changed transplant medicine. Diabetes studies are still a local strength, alongside cancer research at the Cross Cancer Institute, the comprehensive cancer centre for northern Alberta since 1968. Of the roughly 500 studies recruiting in the city, about a third are in oncology, with multiple myeloma and breast cancer among the most common, and the rest span inflammatory bowel disease, pulmonary hypertension, and sleep apnea.
Filter
2
Filter results
Results: 447
FeaturedActive & Responsive
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Edmonton, Vancouver WA, Idaho Falls ID, Littleton CO,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819878
Phase3, Recruiting
Featured
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
for
Non-Segmental Vitiligo (NSV), Alopecia Areata,
Location: Edmonton, Calgary, London, Barrie, Richmond Hill,
Sponsor: AbbVie
Sex: All
Age: 12+
Code: NCT07136467
Recruiting
Featured
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
for
Plaque Psoriasis
Location: Edmonton, Calgary, Winnipeg, Thunder Bay, London,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07039110
Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Edmonton, Clinton UT, Bountiful UT, Salt Lake City UT,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
for
Ulcerative Colitis
Location: Edmonton, Calgary, San Francisco CA, Phoenix AZ,
Sponsor: AbbVie
Sex: All
Age: 2 - 17
Code: NCT07071519
Phase3, Recruiting
Featured
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for
Non Small Cell Lung Cancer
Location: Edmonton, Renton WA, Lancaster CA, Kansas City MO,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT04928846
Phase3, Recruiting
Featured
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
for
Metastatic Colorectal Cancer
Location: Edmonton, Calgary, Seattle WA, Omaha NE, Kansas City MO,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06820463
Phase2, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer